BaseSpace
Correlation
Engine-Public
Sign In
Register
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs2476601
,
EGFR
,
Apoptosis
,
Inflammatory disorder
,
Endothelial cell
,
Avian flu virus
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
antigens cd5
Summary
General Info
Curated Studies
Most Correlated Studies
The Immunological Genome Project - Immune cell lineage differentiation and maturation
CD20+ CD5+ Chronic Lymphocytic Leukemia (CLL) cells cultured with activated T cells or CD40L+ cells
Splenic B-lymphocytes from mice expressing dominant-negative Rag1 (dnRag1) and Tcl1
Conventional dendritic cell (CD1c+) subsets differing in CD5 expression
Follicular B cells with conditional deletion or overexpression of miR-17~92 cluster
Explore Curated Studies Results
Literature
Most Relevant Literature
CD5: from antiquated T cell marker to immunotherapy's new hope.
Loss of CD5-positive T-cells following anti-thymocyte globulin treatment.
Role of CD5 molecular-like on hepatocellular carcinoma.
Clinical Features and Prognosis of Patients with CD5+ Diffuse Large B-Cell Lymphoma].
CD5 Controls Gut Immunity by Shaping the Cytokine Profile of Intestinal T Cells.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects with Relapsed or Refractory T-cell Malignanc…
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressin…
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphobl…
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/LBL
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ